Chemical Development Solutions

Chemical Development Solutions
Product Description

Chemical Development Solutions of GVK BIO provides a convenient, single-site distribution of infrastructure, thereby delivering a seamless and innovative transition of solutions from lab to pilot plant and bulk manufacturing, with speed and quality.

We ensure quality in the process during the design and development phase by understanding the Critical Process Parameters (CPP) and Critical Material Attributes (CMA).
Custom synthesis, including synthesis of reference standards, impurity markers and scaffolds, with rapid turnaround and competitive pricingProcess safety assessment to proactively identify potential hazardous reactions Rich experience in developing innovative process for the NCEs
10+ IND filing support/ year
Scientists have an average of 12+ years of experience in process development
18 molecules in late stage/commercial
7 programs in Phase III for a top 3 pharma companies
Cater to various sectors such as pharmaceutical, specialty chemicals and animal health industry
Our facilities have been inspected and accredited by several global regulatory authorities and major pharma clients. Some of the authoritative bodies include FDA, European Directorate for the Quality of Medicines (EDQM), Ministry of Food and Drug Safety, Pharmaceuticals and Medical Devices Agency (Pmda)

Read more Show less

Aragen Life Sciences

  • IN
  • 2019
    On CPHI since
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Primary activities
Agrochemical
API Producer
Biopharmaceutical
Chemical Development
Clinical Research
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Fine Chemicals Company
Generic APIs producer
Intermediates Manufacturer
Nutraceuticals
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    India
More specifications Fewer specifications
Sales Markets
Show more Show less

Aragen Life Sciences

  • IN
  • 2019
    On CPHI since
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Primary activities
Agrochemical
API Producer
Biopharmaceutical
Chemical Development
Clinical Research
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Fine Chemicals Company
Generic APIs producer
Intermediates Manufacturer
Nutraceuticals
View company profile

More Products from Aragen Life Sciences (2)

  • Contract Manufacturing Solutions

    Product Contract Manufacturing Solutions

    GVK BIO offers long term Contract Manufacturing Solutions in development, validations, DMF filing, manufacturing of New Chemical Entities (NCE), Active Pharmaceutical Ingredients (API) and Intermediates.

    Capabilities:Environment friendly routes under GMP conditions
    Robust and cost-effective p...
  • Formulation and Analytical Solutions

    Product Formulation and Analytical Solutions

    GVK BIO offers a range of Formulation R&D solutions that include pre-formulation studies, formulation development, analytical R&D, reformulation and stability studies. We can also support clinical supplies and manufacturing of exhibit batches in collaboration with our partners and offer standalone ...

Aragen Life Sciences resources (3)

  • CPHI Pharma Award Winners 2022: CEO of the Year – Aragen Life Sciences

    News CPHI Pharma Award Winners 2022: CEO of the Year – Aragen Life Sciences

    In this series of interviews, we speak to the teams behind the winning concepts at CPHI Pharma Awards 2022, in each of the different categories, from digital innovation to CEO of the year. 
    17 Jan 2023
  • Covid-19 preventive measures @ GVK BIO (Video)

    Video Covid-19 preventive measures @ GVK BIO (Video)

    With safety being our highest priority, we continue to be a reliable partner in accelerating research and development of our customers. Here’s a look at some of the precautionary measures taken against Covid19 across GVK BIO’s campuses.
    2020-09-11
  • From Late Pre-clinical to Commercial – Balancing Time and Cost Sensitivities

    Video From Late Pre-clinical to Commercial – Balancing Time and Cost Sensitivities

    Navigating the transition from late pre-clinical stages to commercial success in the biotech and pharmaceutical industries requires a delicate balance between speed and cost efficiency. This session will explore strategic approaches to streamline this critical phase, ensuring timely market entry while controlling cost. It will deep diver into the best practices for managing late-stage development, overcoming regulatory hurdles, and scaling up production. The speaker will share insights on optimizing resource allocation, leveraging innovative technologies, and fostering strategic partnerships to enhance both speed and cost-effectiveness. Attendees will gain actionable strategies to minimize time-to-market and maximize return on investment, ensuring successful commercial launches. Join us to learn how to effectively manage the complexities and sensitivities of advancing from pre-clinical trials to commercial deployment.
    2024-10-21